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THE FIRST two major conferences on FK 506 were at 
satellite meetings of the European Society of Organ 
Transplantation (ESOT). which met in Gothenburg (June 
1987) and Barcelona (October 1989). In both of these 
European conferences. the highly focused objective was to 
assess the potential role of the drug with no name (as FK 
506 came to be called) in improving the results after whole 
organ transplantation. Improvement was construed in 
terms of patient and graft survival. but also as quality of 
life. A prime purpose of this meeting was to examine these 
same clinical issues from the cumulative but still prelimi-
nary experience acquired in more than 30 centers in the 
United States. Europe. and Japan. Clinical reports were 
concentrated on Friday (August 23. 1991). and included 
transplantation of previously forbidden organs such as the 
Intestine. 
The first descriptions of FK 506 were published in 1987 
In Japan. The drug was introduced clinically in early 1989 
as a therapeutic last resort in patients who were rejecting 
their liver grafts in spite of maximum therapy with drug 
cocktails based on cyclosporine (CyA) and steroids. Be-
cause allograft rejection is an analogue of autoimmune 
disease. the ability to rescue a significant number of these 
liver recipients as well as recipients of hearts and kidneys 
from rejection. excited immediate interest in using FK 506 
for a wide variety of autoimmune diseases. The results in 
patients with the skin disease. psoriasis. and nearly a 
dozen other autoimmune disorders were discussed on 
Saturday (August 24. 1991). 
However. the clinical reports of FK 506 are only the tip 
of the iceberg with this drug. Research on FK 506. Cy A. as 
well as a third agent called rapamycin (RPM) has created a 
fruitful new field for sophisticated inquiry about signal 
transduction in cells. These three drugs (FK 506. Cy A. and 
RPM) bind to small molecular weight proteins in the cell 
cytoplasm (called immunophilins) and act by altering the 
way that messages from the environment are conveyed to 
the interior of the cell and ultimately enscribed on the 
nucleus. Because the drugs al,er signal transduction. they 
can be used as probes of signal transduction as described 
at the meeting. 
As discussed. the physiology that is changed by the 
drugs is not limited to that. of cells of the immune system. 
The most extensively studied nonimmunologic function is 
that of growth control. and specifically growth control of 
liver cells. However. the nephrotoxicity. neurotoxicity, 
and diabetogenecity of these drugs may also reflect altered 
signal transduction via the immunophilin network. 
Now that the meeting is over I hope that we have a 
better idea of the potential clinical value and proper use of 
FK 506. as well as a new insight into some previously 
obscure secrets of cell function. 
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